Kite's Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell LymphomaBusiness Wire • 03/21/23
Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479Business Wire • 03/20/23
The 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Spring Break Rally24/7 Wall Street • 03/17/23
Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript)Seeking Alpha • 03/15/23
Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/07/23
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIVBusiness Wire • 02/22/23
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized PatientsBusiness Wire • 02/21/23
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and StrategiesBusiness Wire • 02/21/23
Gilead Sciences, Inc. (GILD) SVB Securities Global Biopharma Conference (Transcript)Seeking Alpha • 02/14/23
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023Business Wire • 02/14/23
Kite's Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaBusiness Wire • 02/09/23